HubSpot Inc vs Immunovant Inc. Common Stock — how do they compare? HubSpot Inc trades at $230.8 (market cap $10.98B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: HubSpot Inc is the larger of the two by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Immunovant Inc. Common Stock for 0 Days on average.
| HUBS | IMVT | |
|---|---|---|
Market Cap | $10.98B | $6.62B |
Volume | 1,027,893 | 1,131,364 |
Sector | Technology | Health |
52-Week High | $494.58 | $44.96 |
52-Week Low | $170.39 | $17.03 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $9.88B | $5.72B |
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 6.86% in the past 24 hours, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $1.7B in 2022 to $3.1B in 2025, with net income turning positive in 2024. Recent analyst day highlighted AI strategy enhancements and margin expansion targets through 2030, while technical indicators show resistance near $232 with RSI suggesting potential overbought conditions.
HUBS presents a mixed outlook with strong fundamental growth offset by high valuation multiples (P/E 78.39) and technical resistance. The consensus price target of $243.65 offers modest upside, supported by 59.6% analyst buy ratings, but risks include competitive pressures in CRM software and execution challenges in AI integration. Cash flow growth and institutional accumulation provide support for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →